Herceptin Price Drop Is ‘Pretty Promising,’ But May Not Be Replicable for All Biologics

The introduction of five Herceptin (trastuzumab) biosimilars contributed to a 21% decline in the cancer drug’s average sales price from the first quarter of 2019 to the second quarter of 2022, according to a study published this month in Health Affairs. Alice J. Chen, the study’s lead author, tells AIS Health that the adoption of Herceptin biosimilars and subsequent price decrease of the biologic is “a pretty promising case” at a time when biosimilars’ cost-saving potential is generating considerable interest.

However, Chen says the uptake of other drugs’ biosimilars has varied, leading to more modest price declines and questions about how much the health care industry will save as a flood of biosimilars becomes available in the U.S. in the coming years.

© 2024 MMIT
Tim Casey

Tim Casey

Tim has worked as a reporter and editor for more than 20 years. Before joining AIS Health in December 2021, he was a business reporter covering the commercial real estate industry’s capital markets for four years. He previously covered health care business issues for two medical publishing companies and high school, college and professional sports for the Sacramento Bee newspaper. Tim has a B.A. in Psychology from the University of Notre Dame and an M.B.A. from Georgetown University.

Related Posts

test-tubes
December 8

More Cancer Indications With Accelerated Approval Are Being Withdrawn

READ MORE
vaccine-needle
June 8

Slew of Adalimumab Biosimilars Expected in July

READ MORE
doctor-speaking-to-a-patient
June 1

Commercial Insurance Restrictions Complicate Biosimilar Adoption

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today